logo
Published on FierceVaccines (http://www.fiercevaccines.com)

Novartis earmarks $500M for new Brazilian vax plant; Hep E vaccine a success in clinical trial;

By John Carroll
Created Aug 26 2010 - 8:13am

Vaccine Market

Novartis is planning to invest about a half billion dollars in a new vaccine plant in Brazil. Report [1]

New Jersey has one of the lowest vaccination rates in the U.S., and health officials in the state say they've seen the trend building for years. Story [2]

The World Health Organization has approved the use of Pfizer's Prevnar 13 pediatric vaccine. Estimates sales of the vaccine are projected to hit up to $6 billion by 2016. Report [3]

Emergent BioSolutions named John Niederhuber, M.D. as a Class III Director for a two-year term that will expire at the 2012 annual meeting of stockholders. Emergent release [4]

Ireland is welcoming the arrival of a new vaccine to guard against meningitis. Story [5]

Vaccine Research

Chinese researchers are reporting the success of a new hepatitis E vaccine in a recent clinical trial. They said that even an incomplete dosing regimen appeared to work against the virus. Story [6]

Merck has agreed to buy a dengue vaccine program from Hawaii Biotech for $3.1 million. Hawaii Biotech filed for bankruptcy at the end of last year. Report [7]

Nabi announced the receipt of a patent for treating and preventing nicotine addiction with NicVAX and related nicotine conjugate vaccines. Nabi release [8]


Source URL:
http://www.fiercevaccines.com/also-noted/novartis-earmarks-500m-new-brazilian-vax-plant-hep-e-vaccine-success-clinical-trial/2010-08-26